We don’t do incremental.
We like outliers.
The big ideas that shake things up.
From Early-Stage Science to IPO
Editas Medicine is harnessing CRISPR-Cas9 gene editing to create genomic medicines for devastating and hard-to-treat diseases, including Usher syndrome and Duschenne muscular dystrophy.
Biomatics Capital’s Dr. Boris Nikolic identified CRISPR as a very powerful game changing technology, after learning of the company through his academic and venture network.
In 2015, the partners of Biomatics played a key role in driving Editas to the next level of growth by leading a $120 million Series B round, marking the largest financial investment to a CRISPR startup. Nikolic joined the board and took an active role in guiding the company to a $94.4 million IPO, which was oversubscribed even in a difficult market.